(News Bulletin 247) – GSK announces that it has entered into an exclusive licensing agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a first-in-class antifungal agent approved by the US FDA for the treatment of vulvovaginal candidiasis (VVC). ) and for reducing the incidence of recurrent CVV (RCVV).
This exclusive license agreement gives GSK the right to market Brexafemme for CVV and RCVV while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a fungal infection potentially fatal.
In return, Scynexis will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties.
‘Brexafemme is an approved new antifungal drug with a broad spectrum of activity against existing and emerging resistant fungal strains. In addition, the transaction consolidates GSK’s synergistic portfolio of innovative late-stage antibiotics’, commented Luke Miels, Chief Commercial Officer of GSK.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
